HRP20191777T1 - Vodena farmaceutska formulacija tapentadola za oralnu primjenu - Google Patents
Vodena farmaceutska formulacija tapentadola za oralnu primjenu Download PDFInfo
- Publication number
- HRP20191777T1 HRP20191777T1 HRP20191777TT HRP20191777T HRP20191777T1 HR P20191777 T1 HRP20191777 T1 HR P20191777T1 HR P20191777T T HRP20191777T T HR P20191777TT HR P20191777 T HRP20191777 T HR P20191777T HR P20191777 T1 HRP20191777 T1 HR P20191777T1
- Authority
- HR
- Croatia
- Prior art keywords
- preparation
- use according
- tapentadol
- dosage form
- pain
- Prior art date
Links
- KWTWDQCKEHXFFR-SMDDNHRTSA-N tapentadol Chemical compound CN(C)C[C@H](C)[C@@H](CC)C1=CC=CC(O)=C1 KWTWDQCKEHXFFR-SMDDNHRTSA-N 0.000 title claims 4
- 229960005126 tapentadol Drugs 0.000 title claims 4
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 208000002193 Pain Diseases 0.000 claims 5
- 239000002552 dosage form Substances 0.000 claims 5
- 239000000839 emulsion Substances 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 239000003755 preservative agent Substances 0.000 claims 3
- 230000002335 preservative effect Effects 0.000 claims 3
- 239000000725 suspension Substances 0.000 claims 3
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 2
- 239000006185 dispersion Substances 0.000 claims 2
- 239000006196 drop Substances 0.000 claims 2
- 239000000499 gel Substances 0.000 claims 2
- 239000000243 solution Substances 0.000 claims 2
- 239000006188 syrup Substances 0.000 claims 2
- 235000020357 syrup Nutrition 0.000 claims 2
- 239000005711 Benzoic acid Substances 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 239000002585 base Substances 0.000 claims 1
- 235000010233 benzoic acid Nutrition 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000012458 free base Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 159000000000 sodium salts Chemical class 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Claims (14)
1. Vodeni farmaceutski pripravak za uporabu u liječenju boli, naznačen time da pripravak sadrži bazu bez tapentadola ili hidrokloridnu sol i daje se oralno, pri čemu navedeni pripravak ne sadrži nikakav konzervans.
2. Pripravak za uporabu sukladno zahtjevu 1, naznačen time, da
(i) dodatno sadrži bafer; i/ili
(ii) ima pH vrijednost u rasponu od 3,0 do 6,5.
3. Pripravak za uporabu sukladno zahtjevu 1 ili 2, naznačen time, da je koncentracija tapentadola jednaka ili manja od 50 mg / mL, u odnosu na ukupni volumen pripravka.
4. Pripravak za uporabu sukladno bilo kojem od prethodnih zahtjeva, koji pokazuje rok trajanja u ubrzanim uvjetima skladištenja od najmanje 3 mjeseca.
5. Pripravak za uporabu sukladno bilo kojem od prethodnih zahtjeva, naznačen time što je izabran iz skupine koja se sastoji od sirupa, kapi, otopina, disperzija, suspenzija i emulzija.
6. Vodeni farmaceutski pripravak koji sadrži bazu bez tapentadola ili njegovu hidrokloridnu sol i prilagođen je za oralnu primjenu, pri čemu navedeni sastav dodatno sadrži konzervans koji je benzojeva kiselina ili njegova natrijeva sol, pri čemu je koncentracija konzervansa u rasponu od 2,5 ± 0,6 mg/mL, u odnosu na ukupni volumen pripravka.
7. Pripravak sukladno zahtjevu 6, naznačen time, da
(i) dodatno sadrži bafer; i/ili
(ii) ima pH vrijednost u rasponu od 3,0 do 6,5.
8. Pripravak sukladno zahtjevu 6 ili 7, naznačen time, što je koncentracija tapentadola jednaka ili manja od 50 mg/mL, u odnosu na ukupni volumen pripravka.
9. Pripravak sukladno bilo kojem od zahtjeva 6 do 8, naznačen time, da pokazuje rok trajanja u ubrzanim uvjetima skladištenja od najmanje 3 mjeseca.
10. Pripravak sukladno bilo kojem od zahtjeva 6 do 9, koji je izabran iz skupine koja se sastoji od sirupa, kapi, otopina, disperzija, suspenzija i emulzija.
11. Farmaceutski oblik doziranja za uporabu u liječenju bola, naznačen time, da oblik doziranja sadrži farmaceutski pripravak prema bilo kojem od zahtjeva 6 do 10.
12. Oblik doziranja za uporabu sukladno zahtjevu 11, koji je odabran iz skupine koja se sastoji od oralnih otopina, oralnih gelova, suspenzija, emulzija i kapsula napunjenih tekućinom ili gelom.
13. Oblik doziranja za uporabu sukladno zahtjevu 11 ili 12, naznačen time, da je prilagođen za primjenu kod pedijatrijskih pacijenata.
14. Pripravak za uporabu sukladno bilo kojem od zahtjeva 1 do 5 ili oblik doziranja za uporabu prema bilo kojem od zahtjeva 11 do 13, naznačen time što je bol izabrana iz skupine koja se sastoji od akutne i kronične boli.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161449287P | 2011-03-04 | 2011-03-04 | |
EP11003601 | 2011-05-03 | ||
EP12708672.6A EP2680832B1 (en) | 2011-03-04 | 2012-03-02 | Aqueous pharmaceutical formulation of tapentadol for oral administration |
PCT/EP2012/000904 WO2012119727A1 (en) | 2011-03-04 | 2012-03-02 | Aqueous pharmaceutical formulation of tapentadol for oral administration |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20191777T1 true HRP20191777T1 (hr) | 2020-01-24 |
Family
ID=44650617
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20191777TT HRP20191777T1 (hr) | 2011-03-04 | 2019-10-01 | Vodena farmaceutska formulacija tapentadola za oralnu primjenu |
HRP20200898TT HRP20200898T1 (hr) | 2011-03-04 | 2020-06-04 | Vodeni farmaceutski pripravak tapentadola za oralnu primjenu |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20200898TT HRP20200898T1 (hr) | 2011-03-04 | 2020-06-04 | Vodeni farmaceutski pripravak tapentadola za oralnu primjenu |
Country Status (23)
Country | Link |
---|---|
US (3) | US20130022670A1 (hr) |
EP (4) | EP3597182A1 (hr) |
JP (3) | JP6046057B2 (hr) |
KR (2) | KR101946790B1 (hr) |
CN (2) | CN107308108A (hr) |
AU (2) | AU2012224952C1 (hr) |
BR (1) | BR112013022495A2 (hr) |
CA (1) | CA2828631C (hr) |
CY (2) | CY1125100T1 (hr) |
DK (2) | DK3287123T3 (hr) |
EA (2) | EA027290B1 (hr) |
ES (1) | ES2756776T3 (hr) |
HR (2) | HRP20191777T1 (hr) |
HU (1) | HUE046557T2 (hr) |
IL (2) | IL227824B (hr) |
LT (2) | LT2680832T (hr) |
MX (2) | MX369121B (hr) |
PL (2) | PL3287123T3 (hr) |
PT (2) | PT3287123T (hr) |
RS (2) | RS59491B1 (hr) |
SI (2) | SI2680832T1 (hr) |
WO (1) | WO2012119727A1 (hr) |
ZA (1) | ZA201306478B (hr) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
DE10361596A1 (de) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
DE102004032049A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
DE102005005449A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
KR101616246B1 (ko) | 2008-01-25 | 2016-05-02 | 그뤼넨탈 게엠베하 | 약제학적 투여형 |
MX2010012039A (es) | 2008-05-09 | 2010-11-30 | Gruenenthal Gmbh | Proceso para la preparacion de una formulacion de polvo intermedia y una forma de dosificacion solida final bajo el uso de un paso de congelacion por rocio. |
MX2012000317A (es) | 2009-07-22 | 2012-02-08 | Gruenenthal Gmbh | Forma de dosificacion de liberacion controlada extruida por fusion en caliente. |
RU2015138422A (ru) | 2009-07-22 | 2018-12-25 | Грюненталь Гмбх | Стабильная при окислении, прочная на излом лекарственная форма |
ES2487244T3 (es) | 2010-09-02 | 2014-08-20 | Grünenthal GmbH | Forma de dosificación resistente a la manipulación que comprende un polímero aniónico |
CA2808219C (en) | 2010-09-02 | 2019-05-14 | Gruenenthal Gmbh | Tamper resistant dosage form comprising inorganic salt |
PL3287123T3 (pl) | 2011-03-04 | 2020-11-02 | Grünenthal GmbH | Wodny preparat farmaceutyczny tapentadolu do podawania doustnego |
ES2712072T3 (es) * | 2011-07-20 | 2019-05-09 | Torrent Pharmaceuticals Ltd | Composición farmacéutica de tapentadol |
AU2012292418B2 (en) | 2011-07-29 | 2017-02-16 | Grunenthal Gmbh | Tamper-resistant tablet providing immediate drug release |
CA2839123A1 (en) | 2011-07-29 | 2013-02-07 | Grunenthal Gmbh | Tamper-resistant tablet providing immediate drug release |
MX356421B (es) | 2012-02-28 | 2018-05-29 | Gruenenthal Gmbh | Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico. |
CN104394851B (zh) | 2012-04-18 | 2017-12-01 | 格吕伦塔尔有限公司 | 抗篡改和抗剂量‑倾泻药物剂型 |
US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
AR096438A1 (es) | 2013-05-29 | 2015-12-30 | Gruenenthal Gmbh | Forma de dosificación resistente al uso indebido con perfil de liberación bimodal, proceso |
CA2907950A1 (en) | 2013-05-29 | 2014-12-04 | Grunenthal Gmbh | Tamper-resistant dosage form containing one or more particles |
BR112016000194A8 (pt) | 2013-07-12 | 2019-12-31 | Gruenenthal Gmbh | forma de dosagem resistente à violação contendo o polímero de acetato de etileno-vinila |
EP2845625A1 (en) | 2013-09-04 | 2015-03-11 | Grünenthal GmbH | Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome |
CN105934241B (zh) | 2013-11-26 | 2020-06-05 | 格吕伦塔尔有限公司 | 通过低温研磨制备粉末状药物组合物 |
WO2015173195A1 (en) * | 2014-05-12 | 2015-11-19 | Grünenthal GmbH | Tamper resistant immediate release capsule formulation comprising tapentadol |
JP2017516789A (ja) | 2014-05-26 | 2017-06-22 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | エタノール過量放出に対して防護されている多粒子 |
PT3273953T (pt) * | 2015-03-27 | 2019-04-01 | Gruenenthal Gmbh | Formulação estável para administração parentérica de tapentadol |
EP3285745A1 (en) | 2015-04-24 | 2018-02-28 | Grünenthal GmbH | Tamper-resistant dosage form with immediate release and resistance against solvent extraction |
CA2998259A1 (en) | 2015-09-10 | 2017-03-16 | Grunenthal Gmbh | Protecting oral overdose with abuse deterrent immediate release formulations |
CN105997862A (zh) * | 2016-07-15 | 2016-10-12 | 蓝佳堂生物医药(福建)有限公司 | 一种口腔溃疡含漱液及其制备方法 |
WO2018055070A1 (en) * | 2016-09-23 | 2018-03-29 | Grünenthal GmbH | Stable formulation for parenteral administration of tapentadol |
EP3585370A1 (en) | 2017-02-23 | 2020-01-01 | Grünenthal GmbH | Tapentadol as local anesthetic |
CN108434042A (zh) * | 2018-05-31 | 2018-08-24 | 武汉新大地环保材料股份有限公司 | 一种新型日化防腐剂及其制备方法 |
EP4011369A1 (en) * | 2020-12-14 | 2022-06-15 | G.L. Pharma GmbH | Aqueous pharmaceutical composition comprising tapentadol tartrate |
Family Cites Families (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8334422D0 (en) | 1983-12-23 | 1984-02-01 | Sterwin Ag | Composition |
GB8334423D0 (en) | 1983-12-23 | 1984-02-01 | Sterwin Ag | Composition |
US4775678A (en) | 1984-10-01 | 1988-10-04 | Schering Corporation | Clotrimazole cream |
AU614465B2 (en) | 1989-04-05 | 1991-08-29 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Medicinal emulsions |
DE4426245A1 (de) | 1994-07-23 | 1996-02-22 | Gruenenthal Gmbh | 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung |
US6183758B1 (en) | 1998-01-29 | 2001-02-06 | Highland Laboratories, Inc. | Phytochemicals, nutrients & medication absorption &/or treatment |
US6211169B1 (en) | 1999-09-29 | 2001-04-03 | Aesgen, Inc. | Stable calcitriol solution for packaging into vials |
FR2809619B1 (fr) | 2000-06-06 | 2004-09-24 | Pharmatop | Nouvelles formulations aqueuses de principes actifs sensibles a l'oxydation et leur procede d'obtention |
US6594193B2 (en) * | 2000-06-22 | 2003-07-15 | Progressent Technologies, Inc. | Charge pump for negative differential resistance transistor |
US6399087B1 (en) | 2000-12-20 | 2002-06-04 | Amphastar Pharmaceuticals, Inc. | Propofol formulation with enhanced microbial inhibition |
DE10109763A1 (de) * | 2001-02-28 | 2002-09-05 | Gruenenthal Gmbh | Pharmazeutische Salze |
US20050176790A1 (en) | 2001-02-28 | 2005-08-11 | Johannes Bartholomaus | Pharmaceutical salts |
DE10112325A1 (de) | 2001-03-13 | 2002-10-02 | Fresenius Kabi De Gmbh | Lagerstabile Fertiginfusionslösungen des Paracetamols |
JP4905616B2 (ja) | 2001-04-19 | 2012-03-28 | ライオン株式会社 | ソフトコンタクトレンズ用点眼剤 |
US6638981B2 (en) | 2001-08-17 | 2003-10-28 | Epicept Corporation | Topical compositions and methods for treating pain |
PE20030527A1 (es) | 2001-10-24 | 2003-07-26 | Gruenenthal Chemie | Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen |
FR2832063B1 (fr) | 2001-11-15 | 2004-08-27 | Aguettant Lab | Procede de production de solutions stables de substances phenoliques et les solutions en resultant |
CA2479350A1 (en) * | 2002-03-15 | 2003-09-25 | Cypress Bioscience, Inc. | Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes |
US20030191187A1 (en) | 2002-04-01 | 2003-10-09 | Lee Fang Yu | Injectable pharmaceutical composition containing a non-steroidal anti-inflammatory drug and method for preparing the same |
US20040101563A1 (en) * | 2002-07-18 | 2004-05-27 | Kundu Subhas C. | Storage stable antihistaminic syrup formulations |
AU2003275329B2 (en) * | 2002-09-13 | 2008-04-03 | Cydex Pharmaceuticals, Inc. | Capsules containing aqueous fill compositions stabilized with derivatized cyclodextrin |
US6888993B2 (en) | 2002-11-27 | 2005-05-03 | Corning Incorporated | Dispersion compensating optical fiber for SMF and transmission link including same |
ITMI20022748A1 (it) * | 2002-12-23 | 2004-06-24 | Eurand Int | Dispersioni solide stabilizzate di farmaco in un carrier organico e procedimento per la loro preparazione. |
SI1599222T1 (sl) | 2003-01-08 | 2009-08-31 | Novartis Vaccines & Diagnostic | Stabilizirani vodni sestavki, ki obsegajo inhibitor poti tkivnega faktorja (TFPI) ali varianto inhibitorja poti tkivnega faktorja |
US20040180915A1 (en) | 2003-03-14 | 2004-09-16 | Xanodyne Pharmacal, Inc. | Methadone-containing compositions for parenteral administration and method of use thereof |
WO2005112926A1 (en) * | 2004-05-17 | 2005-12-01 | Pharmacofore, Inc. | Compositions and methods for treating or preventing pain |
SI1612203T1 (sl) | 2004-06-28 | 2007-12-31 | Gruenenthal Chemie | Kristalne oblike (-)-(1R,2R)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol hidroklorida |
AU2005259478B2 (en) | 2004-07-01 | 2010-07-15 | Gruenenthal Gmbh | Oral dosage form safeguarded against abuse containing (1R, 2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol |
DE102004032103A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
KR20080026090A (ko) * | 2005-04-28 | 2008-03-24 | 테라퀘스트 바이오사이언시즈 엘엘씨 | 통증을 치료하기 위한 방법 및 조성물 |
TWI329334B (en) | 2005-12-02 | 2010-08-21 | Chung Shan Inst Of Science | Manufacture method of electromagnetic interference layer for the plasma display panel |
US20070166336A1 (en) * | 2005-12-13 | 2007-07-19 | David Delmarre | Stable and palatable oral liquid sumatriptan compositions |
US8176534B2 (en) | 2005-12-30 | 2012-05-08 | General Instrument Corporation | Method and apparatus for provisioning a device to access digital rights management (DRM) services in a universal plug and play (UPnP) network |
WO2007127158A2 (en) | 2006-04-25 | 2007-11-08 | Croda, Inc | Modification of percutaneous absorption of topically active materials |
EP2012764B1 (en) | 2006-04-28 | 2011-01-12 | Grünenthal GmbH | Pharmaceutical combination comprising 3-(3-dimethylamino-1-ethyl-2-methyl-propyl) -phenol and paracetamol |
PT2012763E (pt) | 2006-04-28 | 2011-04-29 | Gruenenthal Gmbh | Combinação farmacêutica que compreende 3-(3-dimetilamino-1-etil-2-metil-propil)fenol e um aine |
TWI401237B (zh) * | 2006-07-24 | 2013-07-11 | 3-〔(1r,2r)-3-(二甲基氨基)-1-乙基-2-甲基丙基〕酚之製備 | |
AU2007278224C1 (en) | 2006-07-24 | 2012-06-21 | Grünenthal GmbH | Preparation of (2R,3R)-3-(3-methoxyphenyl)-N,N,2-trimethylpentanamine |
EP1905440A1 (de) | 2006-09-06 | 2008-04-02 | Boehringer Ingelheim Pharma GmbH & Co. KG | Verwendung einer pharmazeutischen Zusammensetzung enthaltend ein Anticholinergikum zur Abtötung von Mikroorganismen und zur Behandlung von Atemwegsinfektionen |
TWI394564B (zh) | 2006-09-21 | 2013-05-01 | Alcon Res Ltd | 自行保存型水性藥學組成物 |
DE102007012165A1 (de) * | 2007-03-12 | 2008-09-18 | Grünenthal GmbH | Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie des Neuropathieschmerzes |
JP2008266168A (ja) | 2007-04-18 | 2008-11-06 | Teika Seiyaku Kk | 眼科用剤 |
EP1985292A1 (en) | 2007-04-23 | 2008-10-29 | Grünenthal GmbH | Titration of tapentadol |
EP1992334A1 (en) | 2007-05-08 | 2008-11-19 | Docpharma NV/SA | Storage-stable formulation of oxidation-sensitive phenolic drug, especially paracetamol, comprises aqueous drug solution deoxygenated by a temperature-controlled manufacturing process of the formulation |
US20090163451A1 (en) * | 2007-11-16 | 2009-06-25 | Frank Porreca | Methods for treating visceral pain |
CN104958282B (zh) | 2007-11-23 | 2018-05-29 | 格吕伦塔尔有限公司 | 他喷他多组合物 |
WO2009076236A2 (en) | 2007-12-06 | 2009-06-18 | Pain Therapeutics, Inc. | Micronized opioid compositions, formulations and dosage forms and methods of making same |
KR101616246B1 (ko) | 2008-01-25 | 2016-05-02 | 그뤼넨탈 게엠베하 | 약제학적 투여형 |
AU2008354622A1 (en) | 2008-04-08 | 2009-10-15 | Acino Pharma Ag | Aqueous pharmaceutical formulation |
AU2009340504A1 (en) * | 2008-10-30 | 2010-08-26 | Grunenthal Gmbh | Novel and potent tapentadol dosage forms |
JP2012514632A (ja) * | 2009-01-09 | 2012-06-28 | パナセア バイオテック リミテッド | 二段階放出型医薬懸濁剤 |
US20100227921A1 (en) * | 2009-03-03 | 2010-09-09 | Shire Llc | Amino acid and peptide carbamate prodrugs of tapentadol and uses thereof |
EP2246044A1 (en) | 2009-04-21 | 2010-11-03 | Pierre Fabre Dermo-Cosmétique | Paediatric solutions comprising a beta-blocker |
US20100272815A1 (en) * | 2009-04-28 | 2010-10-28 | Actavis Group Ptc Ehf | Amorphous form of tapentadol hydrochloride |
NZ597763A (en) | 2009-07-27 | 2014-07-25 | Nocicepta Llc | Methods for treatment of pain |
WO2011016487A1 (ja) * | 2009-08-05 | 2011-02-10 | ナガセ医薬品株式会社 | インジゴカルミン製剤 |
WO2011071400A1 (en) | 2009-12-10 | 2011-06-16 | Tecnimede - Sociedade Técnico-Medicinal, S.A. | Method and composition for preparing stable liquid formulations of paracetamol |
WO2011083304A1 (en) | 2010-01-05 | 2011-07-14 | Shire Llc | Prodrugs of opioids and uses thereof |
EP2552486B1 (en) | 2010-03-30 | 2020-08-12 | Phosphagenics Limited | Transdermal delivery patch |
GB201006200D0 (en) | 2010-04-14 | 2010-06-02 | Ayanda As | Composition |
CN101948397A (zh) * | 2010-09-07 | 2011-01-19 | 天津泰普药品科技发展有限公司 | 镇痛药他喷他多重要中间体的制备方法 |
US20120270848A1 (en) | 2010-10-22 | 2012-10-25 | Galleon Pharmaceuticals, Inc. | Novel Compositions and Therapeutic Methods Using Same |
SI2680833T1 (sl) | 2011-03-04 | 2016-06-30 | Gruenenthal Gmbh | Parenteralno dajanje tapentadola |
PL3287123T3 (pl) | 2011-03-04 | 2020-11-02 | Grünenthal GmbH | Wodny preparat farmaceutyczny tapentadolu do podawania doustnego |
EP2680834B1 (en) | 2011-03-04 | 2017-10-18 | Grünenthal GmbH | Semisolid aqueous pharmaceutical composition containing tapentadol |
IN2012DE00912A (hr) | 2012-03-27 | 2015-09-11 | Fresenius Kabi Oncology Ltd | |
CN103159633B (zh) | 2012-07-06 | 2015-08-12 | 江苏恩华药业股份有限公司 | 他喷他多的制备方法及用于制备他喷他多的化合物 |
GB201309654D0 (en) | 2013-05-30 | 2013-07-17 | Euro Celtique Sa | Method |
CN103735500B (zh) | 2014-01-28 | 2016-01-20 | 江苏华泽医药科技有限公司 | 盐酸他喷他多注射液及其制备方法 |
PT3273953T (pt) | 2015-03-27 | 2019-04-01 | Gruenenthal Gmbh | Formulação estável para administração parentérica de tapentadol |
-
2012
- 2012-03-02 PL PL17189271T patent/PL3287123T3/pl unknown
- 2012-03-02 AU AU2012224952A patent/AU2012224952C1/en active Active
- 2012-03-02 MX MX2017007718A patent/MX369121B/es unknown
- 2012-03-02 ES ES12708672T patent/ES2756776T3/es active Active
- 2012-03-02 JP JP2013555796A patent/JP6046057B2/ja active Active
- 2012-03-02 RS RS20191382A patent/RS59491B1/sr unknown
- 2012-03-02 RS RS20200566A patent/RS60267B1/sr unknown
- 2012-03-02 LT LT12708672T patent/LT2680832T/lt unknown
- 2012-03-02 PL PL12708672T patent/PL2680832T3/pl unknown
- 2012-03-02 MX MX2013010101A patent/MX351584B/es active IP Right Grant
- 2012-03-02 DK DK17189271.4T patent/DK3287123T3/da active
- 2012-03-02 DK DK12708672.6T patent/DK2680832T3/da active
- 2012-03-02 CN CN201710605686.0A patent/CN107308108A/zh active Pending
- 2012-03-02 CN CN201280011672.1A patent/CN103501773A/zh active Pending
- 2012-03-02 PT PT171892714T patent/PT3287123T/pt unknown
- 2012-03-02 BR BR112013022495A patent/BR112013022495A2/pt not_active Application Discontinuation
- 2012-03-02 EP EP19187973.3A patent/EP3597182A1/en active Pending
- 2012-03-02 EA EA201300989A patent/EA027290B1/ru not_active IP Right Cessation
- 2012-03-02 CA CA2828631A patent/CA2828631C/en active Active
- 2012-03-02 EA EA201692443A patent/EA035750B1/ru not_active IP Right Cessation
- 2012-03-02 LT LTEP17189271.4T patent/LT3287123T/lt unknown
- 2012-03-02 PT PT127086726T patent/PT2680832T/pt unknown
- 2012-03-02 SI SI201231677T patent/SI2680832T1/sl unknown
- 2012-03-02 EP EP12708672.6A patent/EP2680832B1/en active Active
- 2012-03-02 SI SI201231778T patent/SI3287123T1/sl unknown
- 2012-03-02 US US13/410,768 patent/US20130022670A1/en not_active Abandoned
- 2012-03-02 EP EP20154395.6A patent/EP3685827A1/en active Pending
- 2012-03-02 HU HUE12708672A patent/HUE046557T2/hu unknown
- 2012-03-02 KR KR1020137026183A patent/KR101946790B1/ko active IP Right Grant
- 2012-03-02 KR KR1020197003032A patent/KR102051800B1/ko active IP Right Grant
- 2012-03-02 EP EP17189271.4A patent/EP3287123B1/en not_active Revoked
- 2012-03-02 WO PCT/EP2012/000904 patent/WO2012119727A1/en active Application Filing
-
2013
- 2013-08-06 IL IL227824A patent/IL227824B/en active IP Right Grant
- 2013-08-28 ZA ZA2013/06478A patent/ZA201306478B/en unknown
-
2016
- 2016-04-07 US US15/093,522 patent/US20160220516A1/en not_active Abandoned
- 2016-11-15 JP JP2016222084A patent/JP6437984B2/ja active Active
- 2016-12-13 AU AU2016273858A patent/AU2016273858B2/en active Active
-
2017
- 2017-10-02 IL IL254854A patent/IL254854B/en unknown
-
2018
- 2018-06-08 JP JP2018109967A patent/JP6735790B2/ja active Active
-
2019
- 2019-10-01 HR HRP20191777TT patent/HRP20191777T1/hr unknown
- 2019-10-10 CY CY20191101063T patent/CY1125100T1/el unknown
- 2019-10-24 US US16/662,392 patent/US11547678B2/en active Active
-
2020
- 2020-06-04 HR HRP20200898TT patent/HRP20200898T1/hr unknown
- 2020-06-04 CY CY20201100500T patent/CY1123023T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20191777T1 (hr) | Vodena farmaceutska formulacija tapentadola za oralnu primjenu | |
HRP20191994T1 (hr) | Formulacije ketorolaka spremne za uporabu | |
ES2911207T3 (es) | Composiciones de insulina de acción rápida | |
HRP20160403T1 (hr) | Liječenje lipodistrofije | |
JP2015527402A5 (hr) | ||
ES2454967T3 (es) | Composiciones y kits de fenilefrina | |
TWI500424B (zh) | 透析前驅物組成物 | |
HRP20160400T1 (hr) | Parenteralna primjena tapentadola | |
HRP20110271T1 (hr) | Farmaceutska kombinacija koja sadrži 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol i nsaid (nesteroidni antiinflamatorni lijek) | |
HRP20221367T1 (hr) | Brzodjelujući inzulinski pripravci | |
JP2016539921A5 (hr) | ||
CA2704778C (en) | Formulations for enhanced bioavailability of orally administered polar agents | |
EA201492021A1 (ru) | Антительный состав | |
BR112014008551A2 (pt) | conjunto de válvulas para uso com recipiente de líquido e frasco de medicamento | |
MX2014013998A (es) | Composiciones antimucosidad a base de xilitol y metodos y composiciones. | |
HRP20211686T1 (hr) | Formulacije intravenozne otopine sa posakonazolom, stabilizirane supstituiranim beta-ciklodekstrinom | |
WO2012092527A1 (en) | Delivery of treatments transdermally for fungal infections and other indications | |
HRP20240034T1 (hr) | Liječenje kardiovaskularnih bolesti | |
JP2012515184A5 (hr) | ||
RU2016119746A (ru) | Стабильный состав инсулина глулизин | |
SI2680834T1 (en) | A semi-aqueous aqueous pharmaceutical composition containing tapentadol | |
JP2014510067A5 (hr) | ||
HRP20191016T1 (hr) | Farmaceutska otopina pemetrekseda | |
KR20120107970A (ko) | 상승적 항바이러스 조성물 및 이의 용도 | |
CN104622855A (zh) | 含有盐酸氨溴索和硫酸沙丁胺醇的口服溶液剂 |